NCI Broadens the Pool of Oncologists Enrolling Patients in Phase III Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 5
Volume 9
Issue 5

BETHESDA, Md-To increase the number of cancer patients participating in phase III clinical trials, the National Cancer Institute has created the Expanded Participation Project (EPP). This pilot program encourages qualified oncologists outside of the 12 NCI-sponsored Cooperative Groups to enter patients into large clinical studies organized by groups.

BETHESDA, Md—To increase the number of cancer patients participating in phase III clinical trials, the National Cancer Institute has created the Expanded Participation Project (EPP). This pilot program encourages qualified oncologists outside of the 12 NCI-sponsored Cooperative Groups to enter patients into large clinical studies organized by groups.

Under EPP, qualified oncologists can enter patients in 16 large clinical trials for breast, lung, prostate, and colorectal cancer. Other phase III trials will be opened up to EPP participating physicians later this year.

The program offers a simplified, Internet-based process for enrolling patients and a direct reimbursement of $1,500 per patient to physicians to cover their research-related time and costs.

NCI expects EPP to become a national program that will significantly reduce the time it takes to accrue the hundreds or thousands of patients necessary for phase III studies. Additional information is available on the EPP website located at http://light.emmes.com/epp

Recent Videos
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.
Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Prospective trial data may help guide treatment planning for patients with inflammatory bowel disease planning to undergo radiotherapy.
Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.
Samantha Shenoy, NP, MSN, emphasized educating patients with multiple myeloma to help prepare them for potential taste alterations after talquetamab.
Related Content